Entera Bio raises $275m for Phase III osteoporosis drug trial...

Entera Bio raised $275 million in a private placement to finance its Phase III clinical trial for an osteoporosis drug.

The capital will support the Israeli company's operations through 2030.

PRO: see who's reacting and what you're missing. See the whole picture →